Corrigendum to “Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications”

Brian Godman; Magdalene Wladysiuk; Stuart McTaggart; Amanj Kurdi; Eleonora Allocati; Mihajlo Jakovljevic; Francis Kalemeera; Iris Hoxha; Anna Nachtnebel; Robert Sauermann; Manfred Hinteregger; Vanda Marković-Peković; Biljana Tubic; Guenka Petrova; Konstantin Tachkov; Juraj Slabý; Radka Nejezchlebova; Iva Selke Krulichová; Ott Laius; Gisbert Selke; Irene Langner; András Harsanyi; András Inotai; Arianit Jakupi; Svens Henkuzens; Kristina Garuolienė; Jolanta Gulbinovič; Patricia Vella Bonanno; Jakub Rutkowski; Skule Ingeberg; Øyvind Melien; Ileana Mardare; Jurij Fürst; Sean MacBride-Stewart; Carol Holmes; Caridad Pontes; Corinne Zara; Marta Turu Pedrola; Mikael Hoffmann; Vasileios Kourafalos; Alice Pisana; Rita Banzi; Stephen Campbell; Bjorn Wettermark

doi:10.1155/2023/9757348

. 2023 Apr 7;2023:9757348. doi: 10.1155/2023/9757348

Corrigendum to “Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications”

Brian Godman ^1,^2,^3,^✉, Magdalene Wladysiuk ^4,⁵, Stuart McTaggart ⁶, Amanj Kurdi ^1,^2,⁷, Eleonora Allocati ⁸, Mihajlo Jakovljevic ^9,^10,¹¹, Francis Kalemeera ¹², Iris Hoxha ¹³, Anna Nachtnebel ¹⁴, Robert Sauermann ¹⁴, Manfred Hinteregger ¹⁴, Vanda Marković-Peković ¹⁵, Biljana Tubic ^16,¹⁷, Guenka Petrova ¹⁸, Konstantin Tachkov ¹⁸, Juraj Slabý ¹⁹, Radka Nejezchlebova ¹⁹, Iva Selke Krulichová ²⁰, Ott Laius ²¹, Gisbert Selke ²², Irene Langner ²², András Harsanyi ²³, András Inotai ²⁴, Arianit Jakupi ²⁵, Svens Henkuzens ²⁶, Kristina Garuolienė ²⁷, Jolanta Gulbinovič ²⁷, Patricia Vella Bonanno ^1,²⁸, Jakub Rutkowski ⁵, Skule Ingeberg ²⁹, Øyvind Melien ²⁹, Ileana Mardare ³⁰, Jurij Fürst ³¹, Sean MacBride-Stewart ³², Carol Holmes ³³, Caridad Pontes ^34,³⁵, Corinne Zara ³⁴, Marta Turu Pedrola ³⁴, Mikael Hoffmann ³⁶, Vasileios Kourafalos ³⁷, Alice Pisana ³⁸, Rita Banzi ⁸, Stephen Campbell ^39,⁴⁰, Bjorn Wettermark ⁴¹

¹Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow G4 0RE, UK

²Division of Public Health Pharmacy and Management, School of Pharmacy, Sefako Makgatho Health Sciences University, Pretoria, South Africa

³School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia

⁴Chair of Epidemiology and Preventive Medicine, Medical College, Jagiellonian University, Krakow, Poland

⁵HTA Consulting, Starowiślna Str. 17/3, 31-038 Krakow, Poland

⁶Public Health Scotland, Gyle Square, 1 South Gyle Crescent, Edinburgh, UK

⁷Department of Pharmacology, College of Pharmacy, Hawler Medical University, Erbil, Iraq

⁸Istituto di Ricerche Farmacologiche “Mario Negri” IRCCS, Milan, Italy

⁹Institute of Advanced Manufacturing Technologies, Peter the Great St. Petersburg Polytechnic University, St. Petersburg, Russia

¹⁰Institute of Comparative Economic Studies, Hosei University Tokyo, Japan

¹¹Department of Global Health Economics and Policy, University of Kragujevac, Serbia

¹²Department of Pharmacy Practice and Policy, Faculty of Health Sciences, University of Namibia, Windhoek, Namibia

¹³Department of Pharmacy, Faculty of Medicine, University of Medicine, Tirana, Albania

¹⁴Dachverband der Österreichischen Sozialversicherungen, Kundmanngasse 21, AT-1030 Vienna, Austria

¹⁵Faculty of Medicine, Department of Social Pharmacy, University of Banja Luka, Banja Luka, Bosnia and Herzegovina

¹⁶Faculty of Medicine, Department of Medicinal Chemistry, University of Banja Luka, Banja Luka, Bosnia and Herzegovina

¹⁷Agency for Medicinal Product and Medical Devices of Bosnia and Herzegovina, 78000 Banja Luka, Bosnia and Herzegovina

¹⁸Faculty of Pharmacy, Department of Social Pharmacy and Pharmacoeconomics, Medical University of Sofia, Sofia, Bulgaria

¹⁹State Institute for Drug Control, Prague, Czech Republic

²⁰Department of Medical Biophysics, Faculty of Medicine in Hradec Králové, Charles University, Simkova 870, 500 03 Hradec Králové, Czech Republic

²¹State Agency of Medicines, Nooruse 1, 50411 Tartu, Estonia

²²Wissenschaftliches Institut der AOK (WIdO), Rosenthaler Straße 31, 10178 Berlin, Germany

²³Department of Health Policy and Health Economics, Eotvos Lorand University, Budapest, Hungary

²⁴Syreon Research Institute and Semmelweis University, Center of Health Technology Assessment, Budapest, Hungary

²⁵Faculty of Pharmacy, UBT Higher Education Institute, Pristina, Kosovo

²⁶Independent Consultant, Riga, Latvia

²⁷Department of Pathology, Forensic Medicine and Pharmacology, Institute of Biomedical Sciences, Faculty of Medicine, Vilnius University, Vilnius, Lithuania

²⁸Department of Health Services Management, University of Malta, Valletta, Malta

²⁹Medicines Committee, Oslo University Hospitals, Oslo, Norway

³⁰Faculty of Medicine, Public Health and Management Department, “Carol Davila” University of Medicine and Pharmacy Bucharest, 050463 Bucharest, Romania

³¹Health Insurance Institute, Miklosiceva 24, SI-1507 Ljubljana, Slovenia

³²Pharmacy Services, Greater Glasgow and Clyde (NHS GGC), Glasgow, UK

³³NHS Lothian, Edinburgh, UK

³⁴Drug Department, Catalan Health Service, Gran Via de les Corts Catalanes, 08007 Barcelona, Spain

³⁵Department of Pharmacology, Therapeutics and Toxicology, Universitat Autònoma de Barcelona, Barcelona, Spain

³⁶NEPI-Nätverk för Läkemedelsepidemiologi, Stockholm, Sweden

³⁷National Organization for the Provision of Healthcare Services (EOPYY), Athens, Greece

³⁸Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden

³⁹Centre for Primary Care and Health Services Research, School of Health Sciences, University of Manchester, Manchester M13 9PL, UK

⁴⁰NIHR Greater Manchester Patient Safety Translational Research Centre, School of Health Sciences, University of Manchester, Manchester, UK

⁴¹Department of Pharmacy, Disciplinary Domain of Medicine and Pharmacy, Uppsala University, Uppsala, Sweden

^✉

Corresponding author.

PMCID: PMC10104731 PMID: 37065720

In the article titled “Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications” [1], the captions of Figures 3 and 4 were incorrect. The corrected captions for Figures 3 and 4 appear below.

Utilisation of insulin glargine 300 IU/ml (Gla-300) as a % of total insulin glargine (DDD based) across Europe over time.

Utilisation of insulin glargine biosimilar (100 IU/ml) as a % of total insulin glargine 100 IU/ml (DDD based) over time across Europe.

References

1.Godman B., Wladysiuk M., McTaggart S., et al. Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications. BioMed Research International . 2021;2021:16. doi: 10.1155/2021/9996193.9996193 [DOI] [PMC free article] [PubMed] [Google Scholar]

[B1] 1.Godman B., Wladysiuk M., McTaggart S., et al. Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications. BioMed Research International . 2021;2021:16. doi: 10.1155/2021/9996193.9996193 [DOI] [PMC free article] [PubMed] [Google Scholar]

PERMALINK

Corrigendum to “Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications”

Brian Godman

Magdalene Wladysiuk

Stuart McTaggart

Amanj Kurdi

Eleonora Allocati

Mihajlo Jakovljevic

Francis Kalemeera

Iris Hoxha

Anna Nachtnebel

Robert Sauermann

Manfred Hinteregger

Vanda Marković-Peković

Biljana Tubic

Guenka Petrova

Konstantin Tachkov

Juraj Slabý

Radka Nejezchlebova

Iva Selke Krulichová

Ott Laius

Gisbert Selke

Irene Langner

András Harsanyi

András Inotai

Arianit Jakupi

Svens Henkuzens

Kristina Garuolienė

Jolanta Gulbinovič

Patricia Vella Bonanno

Jakub Rutkowski

Skule Ingeberg

Øyvind Melien

Ileana Mardare

Jurij Fürst

Sean MacBride-Stewart

Carol Holmes

Caridad Pontes

Corinne Zara

Marta Turu Pedrola

Mikael Hoffmann

Vasileios Kourafalos

Alice Pisana

Rita Banzi

Stephen Campbell

Bjorn Wettermark

Figure 1.

Figure 2.

References

ACTIONS

PERMALINK

RESOURCES

Similar articles

Cited by other articles

Links to NCBI Databases